髄膜炎菌ワクチンの世界市場2020-2027:ブランド別(Menactra、Menveo、Bexsero、Trumenba、Nimenrix)、種類別(2価、4価)、年齢層別、地域別

◆英語タイトル:Meningococcal Vaccine Market Size, Share & Trends Analysis Report By Brand (Menactra, Menveo, Bexsero, Trumenba, Nimenrix), By Type (Bivalent, Quadrivalent), By Age Group, By Region, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20NV076
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年9月16日
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥642,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥750,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥966,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、髄膜炎菌ワクチンの世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、種類別市場規模(2価、4価)、ブランド別市場規模(Menactra、Menveo、Bexsero、Trumenba、Nimenrix)、年齢層別市場規模(乳幼児(0〜2歳)、子供・大人(2歳以上))、地域別市場規模、競争状況などの項目を掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場要因・動向・範囲
・髄膜炎菌ワクチンの世界市場規模:種類別(2価、4価)
・髄膜炎菌ワクチンの世界市場規模:ブランド別(Menactra、Menveo、Bexsero、Trumenba、Nimenrix)
・髄膜炎菌ワクチンの世界市場規模:年齢層別(乳幼児(0〜2歳)、子供・大人(2歳以上))
・髄膜炎菌ワクチンの世界市場規模:地域別
・競争状況
【レポートの概要】

Meningococcal Vaccine Market Growth & Trends

The global meningococcal vaccine market size is expected to reach USD 5.9 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Grand View Research, Inc. Increasing prevalence of meningitis is one of the major factors attributed to the market growth. Furthermore, according to the European Centre for Disease Prevention and Control (ECDC), it was estimated that in 2017, 3,221 confirmed cases were observed in the EU member states, in which 58% of cases were found in the U.K., France, Spain, and Germany.

In addition, manufacturers are receiving Break Through Designation (BTD) for the development of improved vaccines as compared to available therapy. For instance, in February 2018, GlaxoSmithKline plc received BTD for Bexsero for extending its use in the age group below 11 years. Such initiatives are expected to improve meningococcal prevention, which in turn is anticipated to drive the market.

Initiatives undertaken by the government to combat the rising incidence of the disease is anticipated to boost the market growth. For instance, from April 2019, Nimenrix was made available for free as a part of the National Immunisation Program (NIP) for the age group 14 to 16 years. Nimenrix is a single dose quadrivalent meningococcal vaccine that targets serogroups A, C, W & Y.

In addition, rising awareness programs focused on prevention of the target disease is expected to fuel market growth. For instance, in April 2019, the National Day of Action against Meningitis B was launched by the Meningitis B Action Project on World Meningitis Day to improve awareness of meningitis regarding available vaccines such as MenACWY and MenB among healthcare professional, students, and parents.

Furthermore, the government provision of free vaccination to reduce the spread of the target disease is anticipated to boost the market growth. For instance, in November 2018, the government of New Zealand started a free vaccination program in Northland for infants and children.

Non-profit organizations entering into strategic initiatives such as partnering, alliances, and others to improve access to new vaccines for vulnerable children is anticipated to drive the market. For instance, Gavi is a vaccine alliance formed between UNICEF, World Health Organization, the Bill and Melinda Gates Foundation, and the World Bank to help boost economies of low-income countries and improve access to under-used vaccines for children suffering from meningitis.

Moreover, clinical trials conducted on teenagers to develop novel meningococcal vaccines are expected to drive the market. For instance, in March 2018, the National Health Service launched a Meningitis B vaccine trial for teenagers and recruited 24,000 volunteers of age group 16 to 18 years for this study. This clinical trial was funded and supported by the National Institute for Health Research (NIHR).

The availability of vaccines at lower prices in countries with an increasing prevalence of meningococcal diseases is anticipated to fuel the revenue of the manufacturers and drive the market. For instance, under the Meningitis Vaccine Project, MenAfriVac costs less than USD 0.5 per dose.

Meningococcal Vaccine Market Report Highlights

• In 2019, Bexsero was the largest-revenue holding brand in the market owing to its stronger demand in Europe and studies showing a decrease in meningitis cases

• The quadrivalent segment is expected to witness the fastest growth over the forecast period due to its ability to target four serogroups and the availability of vaccines such as Menactra, Menveo, and Nimenrix

• In the case of the age group segment, infants (0 to 2 years) are expected to witness a significant CAGR owing to the increasing prevalence of meningitis in the age group 9 months to 11 years

• Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and rising healthcare expenditure

• North America dominated the market in 2019 due to the presence of key players and rising initiatives to raise awareness among healthcare professionals and patients

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List Of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4
1.9 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Meningococcal Vaccines Market Variables, Trends & Scope
3.1 Key Opportunities Prioritized
3.2 Product Pipeline Analysis
3.3 Regulatory Framework
3.3.1 North America
3.3.2 Europe
3.3.3 Asia Pacific
3.3.4 Latin America
3.3.5 Middle East And Africa
3.4 Market Driver Analysis
3.4.1 Rising Incidence Of Meningitis Disease
3.4.2 Rising R&D In Meningococcal Vaccines
3.4.3 Increasing Immunization Programs And Government Initiatives
3.4.4 Growing Support By Healthcare Services In Providing Low-Cost Meningococcal Vaccine
3.5 Market Restraint Analysis
3.5.1 High Cost Associated With Storage And Supply Of Vaccines
3.6 Swot Analysis; By Factor (Political & Legal, Economic, And Technological)
3.7 Porter’s Five Forces Analysis
3.8 Major Deals And Strategic Alliances Analysis
3.8.1 New Product Launch
3.8.2 Mergers And Acquisitions
3.8.3 Expansion
3.8.4 Partnerships
3.8.5 Marketing & Promotions
3.8.6 Market Entry Strategies
Chapter 4 Meningococcal Vaccines Market: Segment Analysis, By Type, 2016 – 2027 (USD Million)
4.1 Definition And Scope
4.2 Type Market Share Analysis, 2019 & 2027
4.3 Segment Dashboard
4.4 Global Meningococcal Vaccines Market, By Type, 2016 To 2027
4.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027
4.5.1 Bivalent
4.5.1.1 Bivalent Market Estimates And Forecast, 2016 – 2027 (USD Million)
4.5.2 Quadrivalent
4.5.2.1 Quadrivalent Market Estimates And Forecast, 2016 – 2027 (USD Million)
4.5.3 Others
4.5.3.1 Others Market Estimates And Forecast, 2016 – 2027 (USD Million)
Chapter 5 Meningococcal Vaccines Market: Segment Analysis, By Brand, 2016 – 2027 (USD Million)
5.1 Definition And Scope
5.2 Brand Market Share Analysis, 2019 & 2027
5.3 Segment Dashboard
5.4 Global Meningococcal Vaccines Market, By Brand, 2016 To 2027
5.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027
5.5.1 Menactra
5.5.1.1 Menactra Market Estimates And Forecast, 2016 – 2027 (USD Million)
5.5.2 Menveo
5.5.2.1 Menveo Market Estimates And Forecast, 2016 – 2027 (USD Million)
5.5.3 Nimenrix
5.5.3.1 Nimenrix Market Estimates And Forecast, 2016 – 2027 (USD Million)
5.5.4 Trumenba
5.5.4.1 Trumenba Market Estimates And Forecast, 2016 – 2027 (USD Million)
5.5.5 Bexsero
5.5.5.1 Bexsero Market Estimates And Forecast, 2016 – 2027 (USD Million)
5.5.6 Others
5.5.6.1 Others Market Estimates And Forecast, 2016 – 2027 (USD Million)
Chapter 6 Meningococcal Vaccines Market: Segment Analysis, By Age Group, 2016 – 2027 (USD Million)
6.1 Definition And Scope
6.2 Age Group Market Share Analysis, 2019 & 2027
6.3 Segment Dashboard
6.4 Global Meningococcal Vaccines Market, By Age Group, 2016 To 2027
6.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027
6.5.1 Infants (0-2 Years)
6.5.1.1 Infants (0-2 Years) Market Estimates And Forecast, 2016 – 2027 (USD Million)
6.5.2 Children And Adults (2 Years And Above)
6.5.2.1 Children And Adults (2 Years And Above) Market Estimates And Forecast, 2016 – 2027 (USD Million)
Chapter 7 Meningococcal Vaccines Market: Segment Analysis, By Region, 2016 – 2027 (USD Million)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2019 & 2027
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Regional Market Share And Leading Players, 2019
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 Middle East And Africa
7.6 Swot Analysis
7.6.1 North America
7.6.2 Europe
7.6.3 Asia Pacific
7.6.4 Latin America
7.6.5 Middle East And Africa
7.7 Market Size & Forecasts And Trend Analyses, 2016 To 2027
7.7.1 North America
7.7.1.1 North America Market Estimates And Forecasts, 2016 – 2027 (USD Million)
7.7.1.2 The U.S.
7.7.1.2.1 U.S. Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.1.3 Canada
7.7.1.3.1 Canada Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.2 Europe
7.7.2.1 Europe Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.2.2 Germany
7.7.2.2.1 Germany Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.2.3 The U.K.
7.7.2.3.1 The U.K. Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.2.4 France
7.7.2.4.1 France Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.2.5 Spain
7.7.2.5.1 Spain Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.2.6 Italy
7.7.2.6.1 Italy Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.2.7 Russia
7.7.2.7.1 Russia Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.3 Asia Pacific
7.7.3.1 Asia Pacific Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.3.2 Japan
7.7.3.2.1 Japan Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.3.3 China
7.7.3.3.1 China Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.3.4 India
7.7.3.4.1 India Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.3.5 South Korea
7.7.3.5.1 South Korea Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.3.6 Australia
7.7.3.6.1 Australia Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.3.7singapore
7.7.3.7.1 Singapore Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.4 Latin America
7.7.4.1 Latin America Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.4.2 Brazil
7.7.4.2.1 Brazil Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.4.3 Mexico
7.7.4.3.1 Mexico Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.4.4 Argentina
7.7.4.4.1 Argentina Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.5 Middle East & Africa
7.7.5.1 Middle-East And Africa Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.5.2 South Africa
7.7.5.2.1 South Africa Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.5.3 Saudi Arabia
7.7.5.3.1 Saudi Arabia Market Estimate And Forecasts, 2016 – 2027 (USD Million)
7.7.5.4 UAE
7.7.5.4.1 UAE Market Estimate And Forecasts, 2016 – 2027 (USD Million)
Chapter 8 Competitive Landscape
8.1 Recent Developments & Impact Analysis, By Key Market Participants
8.1.1 Ansoff Matrix
8.1.2 Company/Competition Categorization (Key Innovators, Market Leaders, Expansion)
8.1.3 Innovators
8.2 Vendor Landscape
8.2.1 List Of Key Distributors And Channel Partners
8.2.2 Key Company Market Share Analysis, 2019
8.3 Public Companies
8.3.1 Company Market Position Analysis
8.3.2 Competitive Dashboard Analysis
8.4 Private Companies
8.4.1 Key Emerging Companies /Technology Disruptors/Innovators
8.4.2 Regional Network Map
8.5 Company Profile
8.5.1 Sanofi
8.5.1.1 Company Overview
8.5.1.2 Financial Performance
8.5.1.3 Product Benchmarking
8.5.1.4 Strategic Initiatives
8.5.2 Merck & Co., Inc.
8.5.2.1company Overview
8.5.2.2 Financial Performance
8.5.2.3 Product Benchmarking
8.5.2.4 Strategic Initiatives
8.5.3 GlaxoSmithKline Plc.
8.5.3.1company Overview
8.5.3.2 Financial Performance
8.5.3.3 Product Benchmarking
8.5.3.4 Strategic Initiatives
8.5.4 Serum Institute Of India Pvt. Ltd.
8.5.4.1 Company Overview
8.5.4.2 Product Benchmarking
8.5.4.3 Strategic Initiatives
8.5.5 Pfizer Inc.
8.5.5.1 Company Overview
8.5.5.2 Financial Performance
8.5.5.3 Product Benchmarking
8.5.5.4 Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 Product pipeline
Table 4 CDC Vaccine Price List
Table 5 List of key emerging companies /technology disruptors/innovators
Table 6 America Meningococcal Vaccines Market, By Country, 2016 - 2027 (USD Million)
Table 7 North America Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 8 North America Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 9 North America Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 10 The U.S. Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 11 The U.S. Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 12 The U.S. Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 13 Canada Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 14 Canada Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 15 Canada Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 16 Europe Meningococcal Vaccines Market, By Country, 2016 - 2027 (USD Million)
Table 17 Europe Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 18 Europe Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 19 Europe Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 20 Germany Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 21 Germany Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table22 Germany Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 23 The U.K. Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 24 The U.K. Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 25 The U.K. Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 26 France Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 27 France Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 28 France Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 29 Italy Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 30 Italy Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 31 Italy Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 32 Spain Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 33 Spain Meningococcal VaccinesMarket, By Brand, 2016 - 2027 (USD Million)
Table 34 Spain Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 35 Russia Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 36 Russia Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 37 Russia Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 39 Asia Pacific Meningococcal Vaccines Market, By Country, 2016 - 2027 (USD Million)
Table 40 Asia Pacific Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 41 Asia Pacific Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 42 Asia Pacific Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 43 Japan Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 44 Japan Meningococcal Vaccines Market, By Brand 2016 - 2027 (USD Million)
Table 45 Japan Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 46 China Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 47 China Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 48 China Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 49 India Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 50 India Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 51 India Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 52 Australia Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 53 Australia Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 54 Australia Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 55 Singapore Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 56 Singapore Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 57 Singapore Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 58 South Korea Meningococcal Vaccines Market, By Type 2016 - 2027 (USD Million)
Table 59 South Korea Meningococcal VaccinesMarket, By Brand, 2016 - 2027 (USD Million)
Table 60 South Korea Meningococcal VaccinesMarket, By Age Group, 2016 - 2027 (USD Million)
Table 61 Latin America Meningococcal Vaccines Market, By Country, 2016 - 2027 (USD Million)
Table 62 Latin America Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 63 Latin America Meningococcal VaccinesMarket, By Brand, 2016 - 2027 (USD Million)
Table 64 Latin America Meningococcal VaccinesMarket, By Age Group, 2016 - 2027 (USD Million)
Table 65 Brazil Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 66 Brazil Meningococcal Vaccines Market, By Brand 2016 - 2027 (USD Million)
Table 67 Brazil Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 68 Mexico Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 69 Mexico Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 70 Mexico Meningococcal VaccinesMarket, By Age Group, 2016 - 2027 (USD Million)
Table 71 Argentina Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 72 Argentina Meningococcal VaccinesMarket, By Brand, 2016 - 2027 (USD Million)
Table 73 Argentina Meningococcal VaccinesMarket, By Age Group, 2016 - 2027 (USD Million)
Table 74 Middle East & Africa Meningococcal Vaccines Market, By Country, 2016 - 2027 (USD Million)
Table 75 Middle East & Africa Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 76 Middle East & Africa Meningococcal VaccinesMarket, By Brand, 2016 - 2027 (USD Million)
Table 77 Middle East & Africa Meningococcal VaccinesMarket, By Age Group, 2016 - 2027 (USD Million)
Table 78 Saudi Arabia Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 79 Saudi Arabia Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 80 Saudi Arabia Meningococcal VaccinesMarket, By Age Group, 2016 - 2027 (USD Million)
Table 81 South Africa Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 82 South Africa Meningococcal VaccinesMarket, By Brand, 2016 - 2027 (USD Million)
Table 83 South Africa Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)
Table 84 UAE Meningococcal Vaccines Market, By Type, 2016 - 2027 (USD Million)
Table 85 UAE Meningococcal Vaccines Market, By Brand, 2016 - 2027 (USD Million)
Table 86 UAE Meningococcal Vaccines Market, By Age Group, 2016 - 2027 (USD Million)

List of Figures

Fig. 1 Meningococcal vaccines market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Meningococcal vaccines market snapshot
Fig. 10 Key market opportunities
Fig. 11 Meningococcal vaccines market driver impact
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 SWOT analysis, by factor (Political & legal, economic, and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Strategy mapping
Fig. 16 Meningococcal vaccines market: Type movement analysis
Fig. 17 Meningococcal vaccines: Type segment dashboard
Fig. 18 Meningococcal vaccines market type outlook: Key takeaways
Fig. 19 Bivalent market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 20 Quadrivalent market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 21 Others market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 22 Meningococcal vaccines market: Brand movement analysis
Fig. 23 Meningococcal vaccines: Brand segment dashboard
Fig. 24 Meningococcal vaccines market Brand outlook: Key takeaways
Fig. 25 Menactra market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 26 Menveo market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 27 Nimenrix market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 28 Trumenba market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 29 Bexsero market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 30 Others market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 31 Meningococcal vaccines market: Age group movement analysis
Fig. 32 Meningococcal vaccines: Age group segment dashboard
Fig. 33 Meningococcal vaccines market age group outlook: Key takeaways
Fig. 34 Infants (0-2 years) market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 35 Children and adults (2 years and above) market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 36 Regional outlook, 2019 & 2027
Fig. 37 Regional market dashboard
Fig. 38 Regional market place: Key takeaways
Fig. 39 North America market share and key players (2019)
Fig. 40 Europe market share and key players (2019)
Fig. 41 Asia Pacific market share and key players (2019)
Fig. 42 Latin America market share and key players (2019)
Fig. 43 Middle East and Africa market share and key players (2019)
Fig. 44 North America, SWOT
Fig. 45 Europe, SWOT
Fig. 46 Asia Pacific, SWOT
Fig. 47 Latin America, SWOT
Fig. 48 Middle East and Africa, SWOT
Fig. 49 North America
Fig. 50 North America market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 51 The U.S.
Fig. 52 The U.S. market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 53 Canada
Fig. 54 Canada market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 55 Europe
Fig. 56 Europe market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 57 Germany
Fig. 58 Germany market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 59 The U.K.
Fig. 60 The U.K. market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 61 France
Fig. 62 France market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 63 Spain
Fig. 64 Spain market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 65 Italy
Fig. 66 Italy market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 67 Russia
Fig. 68 Russia market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 69 Asia Pacific
Fig. 70 Asia Pacific market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 71 Japan
Fig. 72 Japan market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 73 China
Fig. 74 China market estimate and forecasts, 2016-2027
Fig. 75 India
Fig. 76 India market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 77 South Korea
Fig. 78 South Korea market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 79 Australia
Fig. 80 Australia market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 81 Singapore
Fig. 82 Singapore market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 83 Latin America
Fig. 84 Latin America market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 85 Brazil
Fig. 86 Brazil market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 87 Mexico
Fig. 88 Mexico market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 89 Argentina
Fig. 90 Argentina market estimate and forecasts, 2016 - 2027 (USD Million)
Fig. 91 Middle East & Africa
Fig. 92 Middle East and Africa market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 93 South Africa
Fig. 94 South Africa market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 95 Saudi Arabia
Fig. 96 Saudi Arabia market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 97 UAE
Fig. 98 UAE market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 99 Ansoff Matrix
Fig. 100 Competition Categorization
Fig. 101 Company market share analysis
Fig. 102 Company market position analysis
Fig. 103 Company market position analysis
Fig. 104 Competitive dashboard analysis
Fig. 105 Regional Network Map
Fig. 106 Strategy Framework

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[髄膜炎菌ワクチンの世界市場2020-2027:ブランド別(Menactra、Menveo、Bexsero、Trumenba、Nimenrix)、種類別(2価、4価)、年齢層別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆